Asset Details
Do you wish to reserve the book?
Cholestyramine: an inexpensive but overlooked treatment for long-acting anticoagulant rodenticide (LAAR) poisoning
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Cholestyramine: an inexpensive but overlooked treatment for long-acting anticoagulant rodenticide (LAAR) poisoning
Do you wish to request the book?
Cholestyramine: an inexpensive but overlooked treatment for long-acting anticoagulant rodenticide (LAAR) poisoning
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Cholestyramine: an inexpensive but overlooked treatment for long-acting anticoagulant rodenticide (LAAR) poisoning
2024
Overview
Treatment of long-acting, anticoagulant rodenticides (LAAR)-poisoned patients with high-dose oral vitamin K1 (VK1) is expensive and requires several months. The long duration can result in non-adherence leading to recurrent severe coagulopathy, bleeding, and hospitalizations. Cholestyramine (CSA) is an inexpensive, safe, and effective gut-restricted resin used to treat primary hypercholesterolemia or pruritus, and to accelerate clearance of teriflunomide. We propose using inexpensive CSA therapy in LAAR-poisoned patients while administering daily high-dose oral VK1 and periodically monitoring plasma LAAR concentrations until declining to a safe concentration. We suggest that this regimen should be available to public health clinics responding to outbreaks of LAAR poisoning. CSA treatment could improve patient adherence, shorten duration of high dose oral VK1 therapy, and reduce healthcare expenditures.
Publisher
Taylor & Francis Group
Subject
We currently cannot retrieve any items related to this title. Kindly check back at a later time.